- BusinessThe Street•3 hours ago
There was a time when the underperformance of Gilead Sciences' (GILD) stock price was viewed as an opportunity to buy shares of a historically great biotech company at a discount. But Gilead's stock price continues to fall, trading today where it did two years ago. The value play looks more like a trap. Investors once okay with waiting patiently for a Gilead rebound are growing frustrated, even angry, at the company's lack of progress. (I wrote about the challenges to Gilead's M&A growth strategy in July.) It's reaching the point now where Gilead CEO John Milligan (and before him, John Martin) is at risk of losing his perennial status as biotech's best, most trusted CEO. "Investors have broadly
- EntertainmentMarketWatch•51 minutes ago
Robert Kiyosaki, author of several best-selling books including “Rich Dad Poor Dad,” joined MarketWatch for a live interview on Facebook today. He offered up insights on making money, becoming an entrepreneur and even touched on politics. Here are some highlights from the talk, or you can listen to the full interview here. His advice on how to get rich: “The rich do not work for money. Most people do not understand that, because they’re taught to go to school and get a job for money. The rich don’t work for money. Check out: Get ready for a 5%-10% stock-market drop And one of the reasons for that is money is no longer money. One of the reasons for that is in 1971, President Nixon took the U.S.
- financeBloomberg•4 hours ago
Saudi Arabia, the world’s biggest oil exporter, won’t boost output to capacity and flood the market, the kingdom’s Energy Minister Khalid Al-Falih said as OPEC members plan to meet next month to discuss ...